Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

OBJECTIVE: The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown whether patients who fail to respond to the first onabotulinumtoxinA treatment cycle will respond to subsequent treatment c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Neurol Neurosurg Psychiatry
Main Authors: Silberstein, Stephen D, Dodick, David W, Aurora, Sheena K, Diener, Hans-Christoph, DeGryse, Ronald E, Lipton, Richard B, Turkel, Catherine C
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2015
Fag:
Migraine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552933/
https://ncbi.nlm.nih.gov/pubmed/25500317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2013-307149
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker